tiprankstipranks
Anika Therapeutics (DE:AKP)
FRANKFURT:AKP
Germany Market
AKP
Anika Therapeutics
RESEARCH TOOLSreports

Anika Therapeutics (AKP) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

AKP Analyst Ratings

Moderate Buy
2Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
Based on 2 analysts giving stock ratings to
Anika
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AKP Stock 12 Month Forecast

Average Price Target

€18.24
▲(43.63% Upside)
Based on 2 Wall Street analysts offering 12 month price targets for Anika Therapeutics in the last 3 months. The average price target is €18.24 with a high forecast of €18.24 and a low forecast of €18.24. The average price target represents a 43.63% change from the last price of €12.70.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"€6","19":"€19","9.25":"€9.25","12.5":"€12.5","15.75":"€15.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18.24037698,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€18.24</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.24037698,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€18.24</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.24037698,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€18.24</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,9.25,12.5,15.75,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.7,14.97233669076923,15.244673381538462,15.517010072307691,15.789346763076923,16.061683453846154,16.334020144615383,16.606356835384616,16.878693526153846,17.151030216923075,17.42336690769231,17.695703598461538,17.96804028923077,{"y":18.24037698,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.7,14.97233669076923,15.244673381538462,15.517010072307691,15.789346763076923,16.061683453846154,16.334020144615383,16.606356835384616,16.878693526153846,17.151030216923075,17.42336690769231,17.695703598461538,17.96804028923077,{"y":18.24037698,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.7,14.97233669076923,15.244673381538462,15.517010072307691,15.789346763076923,16.061683453846154,16.334020144615383,16.606356835384616,16.878693526153846,17.151030216923075,17.42336690769231,17.695703598461538,17.96804028923077,{"y":18.24037698,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.15,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.95,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.55,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.45,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.05,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.1,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.3,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.1,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.2,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.7,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€18.24Average Price Target€18.24Lowest Price Target€18.24
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barrington Analyst forecast on DE:AKP
Michael Petusky
Barrington
Barrington
€14.77→€18.24
Buy
43.63%
Upside
Reiterated
07/30/26
Anika Therapeutics price target raised to $21 from $17 at BarringtonAnika Therapeutics price target raised to $21 from $17 at Barrington
B. Riley Securities Analyst forecast on DE:AKP
Anderson Schock
B. Riley Securities
B. Riley Securities
€15.63→€18.24
Buy
43.63%
Upside
Reiterated
07/30/26
Anika Therapeutics price target raised to $21 from $18 at B. RileyAnika Therapeutics price target raised to $21 from $18 at B. Riley
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barrington Analyst forecast on DE:AKP
Michael Petusky
Barrington
Barrington
€14.77→€18.24
Buy
43.63%
Upside
Reiterated
07/30/26
Anika Therapeutics price target raised to $21 from $17 at BarringtonAnika Therapeutics price target raised to $21 from $17 at Barrington
B. Riley Securities Analyst forecast on DE:AKP
Anderson Schock
B. Riley Securities
B. Riley Securities
€15.63→€18.24
Buy
43.63%
Upside
Reiterated
07/30/26
Anika Therapeutics price target raised to $21 from $18 at B. RileyAnika Therapeutics price target raised to $21 from $18 at B. Riley
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
ZURAZura Bio
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Anika Therapeutics

3 Months
Michael PetuskyBarrington
Success Rate
20/29 ratings generated profit
69%
Average Return
+3.37%
Copying Michael Petusky's trades and holding each position for 3 Months would result in 68.97% of your transactions generating a profit, with an average return of +3.37% per trade.
1 Year
Michael PetuskyBarrington
Success Rate
11/29 ratings generated profit
38%
Average Return
+3.59%
Copying Michael Petusky's trades and holding each position for 1 Year would result in 37.93% of your transactions generating a profit, with an average return of +3.59% per trade.
2 Years
Michael PetuskyBarrington
Success Rate
10/29 ratings generated profit
34%
Average Return
+3.19%
Copying Michael Petusky's trades and holding each position for 2 Years would result in 34.48% of your transactions generating a profit, with an average return of +3.19% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AKP Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
0
Buy
3
1
1
2
2
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
3
1
1
2
2
In the current month, AKP has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AKP average Analyst price target in the past 3 months is 18.24.
Each month's total comprises the sum of three months' worth of ratings.

AKP Financial Forecast

AKP Earnings Forecast

Next quarter’s earnings estimate for AKP is €0.20 with a range of €0.04 to €0.36. The previous quarter’s EPS was €0.36. AKP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 40.59% of the time in the same period. In the last calendar year AKP has Performed in-line its overall industry.
Next quarter’s earnings estimate for AKP is €0.20 with a range of €0.04 to €0.36. The previous quarter’s EPS was €0.36. AKP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 40.59% of the time in the same period. In the last calendar year AKP has Performed in-line its overall industry.

AKP Sales Forecast

Next quarter’s sales forecast for AKP is €25.83M with a range of €25.54M to €26.12M. The previous quarter’s sales results were €28.32M. AKP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year AKP has Performed in-line its overall industry.
Next quarter’s sales forecast for AKP is €25.83M with a range of €25.54M to €26.12M. The previous quarter’s sales results were €28.32M. AKP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year AKP has Performed in-line its overall industry.

AKP Stock Forecast FAQ

What is DE:AKP’s average 12-month price target, according to analysts?
Based on analyst ratings, Anika Therapeutics’s 12-month average price target is 18.24.
    What is DE:AKP’s upside potential, based on the analysts’ average price target?
    Anika Therapeutics has 43.63% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Anika Therapeutics a Buy, Sell or Hold?
          Anika Therapeutics has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Anika Therapeutics’s share price target?
            The average share price target for Anika Therapeutics is 18.24. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €18.24 ,and the lowest forecast is €18.24. The average share price target represents 43.63% Increase from the current price of €12.7.
              What do analysts say about Anika Therapeutics?
              Anika Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
                How can I buy shares of Anika Therapeutics?
                To buy shares of DE:AKP, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.